MedTrace Logo

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

NCT05985343 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2025-11-21

No results posted yet for this study

Summary

The aim of the study is to determine if the usage of sugammadex would reduce the time to return of bowel function when compared to standard of care (neostigmine/glycopyrrolate) when used for neuromuscular blockade reversal in patients with open abdominal wall reconstruction (AWR).

Conditions

  • Hernia, Ventral
  • Ileus

Interventions

DRUG

Neostigmine / Glycopyrrolate

Patients will receive standard of care for reversal of neuromuscular blockade

DRUG

Sugammadex

Patients will receive sugammadex for reversal of neuromuscular blockade

Sponsors & Collaborators

  • Clayton Petro

    lead OTHER

Principal Investigators

  • Clayton C Petro, MD · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2025-05-30
Completion
2025-06-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05985343 on ClinicalTrials.gov